Valuation Update With 7 Day Price Move • May 29
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩2,630, the stock trades at a trailing P/E ratio of 53.8x. Average trailing P/E is 21x in the Life Sciences industry in South Korea. Total loss to shareholders of 68% over the past three years. Duyuru • Mar 17
Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026 Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: sky garden hall, 5806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South Korea New Risk • Mar 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩44.8b market cap, or US$30.6m). Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩3,190, the stock trades at a trailing P/E ratio of 57x. Average trailing P/E is 17x in the Life Sciences industry in South Korea. Total loss to shareholders of 62% over the past three years. New Risk • Nov 16
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 7.6% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩42.6b market cap, or US$29.3m). Duyuru • Aug 27
Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares. Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till February 26, 2026. As of August 26, 2025, the company had 237,458 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities. Duyuru • Mar 15
Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025 Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South Korea New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩53.7b market cap, or US$37.4m). Duyuru • Jul 30
Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares. Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till January 29, 2025. As of July 29, 2024, the company had 30,735 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities. New Risk • Nov 28
New major risk - Revenue and earnings growth Earnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 0.2% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩95.1b market cap, or US$73.4m). New Risk • Jun 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (65% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (0.5% net profit margin). Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩123.1b market cap, or US$95.0m). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Jun 22
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩7,110, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 3.6% over the past three years. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Feb 18
Investor sentiment improved over the past week After last week's 31% share price gain to ₩8,990, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 25x in the Life Sciences industry in South Korea. Negligible returns to shareholders over past three years. Duyuru • Aug 25
Biotoxtech Co., Ltd. announced that it has received KRW 18 billion in funding from BNK Securities Co., Ltd., Investment Arm, Mirae Asset Securities Co., Ltd. and other investors On August 24, 2021, Biotoxtech Co., Ltd. closed the transaction. Duyuru • Aug 21
Biotoxtech Co., Ltd. announced that it expects to receive KRW 18000 billion in funding from BNK Securities Co., Ltd., Investment Arm Biotoxtech Co., Ltd. Is New 90 Day High Low • Feb 18
New 90-day low: ₩11,200 The company is down 29% from its price of ₩15,700 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 2.0% over the same period. Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₩16,700, the stock is trading at a trailing P/E ratio of 57.4x, down from the previous P/E ratio of 68.9x. This compares to an average P/E of 62x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 127%. Valuation Update With 7 Day Price Move • Nov 30
Market bids up stock over the past week After last week's 15% share price gain to ₩20,300, the stock is trading at a trailing P/E ratio of 69.7x, up from the previous P/E ratio of 60.4x. This compares to an average P/E of 102x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 150%. Is New 90 Day High Low • Nov 19
New 90-day high: ₩16,050 The company is up 59% from its price of ₩10,100 on 21 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 3.0% over the same period. Is New 90 Day High Low • Sep 25
New 90-day high: ₩14,200 The company is up 42% from its price of ₩9,970 on 26 June 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 12% over the same period.